We serve Chemical Name:isodehydroacetic acid CAS:480-65-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:isodehydroacetic acid
CAS.NO:480-65-9
Synonyms:4,6-DIMETHYL-2-OXO-2H-PYRAN-5-CARBOXYLIC ACID;EINECS 207-554-4;ISODEHYDRACETIC ACID;Isodehydroacetic acid;2,4-dimethyl-6-oxopyran-3-carboxylic acid;MFCD00023864
Molecular Formula:C8H8O4
Molecular Weight:168.14700
HS Code:2932209090
Physical and Chemical Properties:
Melting point:154-156ºC
Boiling point:303.4ºC at 760mmHg
Density:1.326g/cm3
Index of Refraction:1.4530 (estimate)
PSA:67.51000
Exact Mass:168.04200
LogP:0.95480
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,6-DIMETHYL-2-OXO-2H-PYRAN-5-CARBOXYLIC ACID chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00023864 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-dimethyl-6-oxopyran-3-carboxylic acid Use and application,MFCD00023864 technical grade,usp/ep/jp grade.
Related News: We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently. isodehydroacetic acid manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). isodehydroacetic acid supplier We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently. isodehydroacetic acid vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. isodehydroacetic acid factory Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology.
